AR032432A1 - Combinaciones oncoliticas para el tratamiento de cancer - Google Patents

Combinaciones oncoliticas para el tratamiento de cancer

Info

Publication number
AR032432A1
AR032432A1 ARP000105955A ARP000105955A AR032432A1 AR 032432 A1 AR032432 A1 AR 032432A1 AR P000105955 A ARP000105955 A AR P000105955A AR P000105955 A ARP000105955 A AR P000105955A AR 032432 A1 AR032432 A1 AR 032432A1
Authority
AR
Argentina
Prior art keywords
oncolitical
combinations
cancer treatment
ltb4
effectiveness
Prior art date
Application number
ARP000105955A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR032432A1 publication Critical patent/AR032432A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los antagonistas de leucotrieno (LTB4) mejoran la efectividad de agentes anti-cáncer de 2' û2' difluoronucleosido.
ARP000105955A 1999-11-11 2000-11-10 Combinaciones oncoliticas para el tratamiento de cancer AR032432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11

Publications (1)

Publication Number Publication Date
AR032432A1 true AR032432A1 (es) 2003-11-12

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105955A AR032432A1 (es) 1999-11-11 2000-11-10 Combinaciones oncoliticas para el tratamiento de cancer

Country Status (22)

Country Link
EP (1) EP1231938A2 (es)
JP (1) JP2003513916A (es)
KR (1) KR20020069512A (es)
CN (1) CN1390139A (es)
AR (1) AR032432A1 (es)
AU (1) AU778829B2 (es)
BR (1) BR0015490A (es)
CA (1) CA2391416A1 (es)
CZ (1) CZ20021551A3 (es)
EA (1) EA200200545A1 (es)
HK (1) HK1050132A1 (es)
HU (1) HUP0204449A3 (es)
IL (1) IL148579A0 (es)
MX (1) MXPA02004733A (es)
NO (1) NO20022245L (es)
NZ (1) NZ517667A (es)
PE (1) PE20010701A1 (es)
PL (1) PL355172A1 (es)
SK (1) SK6492002A3 (es)
TR (1) TR200201245T2 (es)
WO (1) WO2001034137A2 (es)
ZA (1) ZA200202822B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
WO2001085166A1 (en) * 2000-05-09 2001-11-15 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
CN1302782C (zh) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 盐酸吉西他滨溶液型注射剂
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
JP5207972B2 (ja) 2006-10-12 2013-06-12 株式会社医薬分子設計研究所 カルボン酸誘導体
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN104884449A (zh) 2012-10-31 2015-09-02 拜尔农作物科学股份公司 作为害虫防治剂的新的杂环化合物
CN103319466B (zh) * 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
AU1599001A (en) 2001-06-06
CZ20021551A3 (cs) 2003-02-12
JP2003513916A (ja) 2003-04-15
NO20022245L (no) 2002-07-09
EA200200545A1 (ru) 2002-12-26
ZA200202822B (en) 2003-09-23
AU778829B2 (en) 2004-12-23
KR20020069512A (ko) 2002-09-04
NO20022245D0 (no) 2002-05-10
NZ517667A (en) 2004-05-28
WO2001034137A3 (en) 2002-02-14
HK1050132A1 (zh) 2003-06-13
SK6492002A3 (en) 2003-09-11
TR200201245T2 (tr) 2004-08-23
MXPA02004733A (es) 2002-08-30
WO2001034137A2 (en) 2001-05-17
HUP0204449A2 (hu) 2003-04-28
CA2391416A1 (en) 2001-05-17
CN1390139A (zh) 2003-01-08
PL355172A1 (en) 2004-04-05
PE20010701A1 (es) 2001-07-07
BR0015490A (pt) 2002-07-09
EP1231938A2 (en) 2002-08-21
HUP0204449A3 (en) 2006-02-28
IL148579A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AR032432A1 (es) Combinaciones oncoliticas para el tratamiento de cancer
DE69907977D1 (de) Pyrrolobenzodiazepine
ATE302775T1 (de) Carbolinderivate
DE60020812D1 (de) Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
PT1200412E (pt) Agentes anti-proliferativos de imidazole
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
ATE346067T1 (de) Carbolinderivate
ITTO20000211A0 (it) Dispositivo combinatore di erogazione per l'alimentazione di apparecchi idraulici.
NO995823L (no) Terapeutisk middel for ereksjonsdysfunksjon
SE9903997D0 (sv) New compounds
SE9901077D0 (sv) Novel use
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60112960D1 (de) Kondensierte pyridoindolderivate
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
IT1319267B1 (it) Apparecchiatura per impedire la sfilacciatura di linee di cuciture.
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
RU97115190A (ru) Антисептическое средство для обработки воды
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
PE20010744A1 (es) Uso de (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol para el tratamiento de la obesidad
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.

Legal Events

Date Code Title Description
FB Suspension of granting procedure